CA2460749C - Glycoconjugate vaccines for use in immune-compromised populations - Google Patents

Glycoconjugate vaccines for use in immune-compromised populations Download PDF

Info

Publication number
CA2460749C
CA2460749C CA2460749A CA2460749A CA2460749C CA 2460749 C CA2460749 C CA 2460749C CA 2460749 A CA2460749 A CA 2460749A CA 2460749 A CA2460749 A CA 2460749A CA 2460749 C CA2460749 C CA 2460749C
Authority
CA
Canada
Prior art keywords
type
patients
vaccine
immune
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2460749A
Other languages
English (en)
French (fr)
Other versions
CA2460749A1 (en
Inventor
Ali I. Fattom
Robert B. Naso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2460749A1 publication Critical patent/CA2460749A1/en
Application granted granted Critical
Publication of CA2460749C publication Critical patent/CA2460749C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2460749A 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations Expired - Lifetime CA2460749C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations
US09/955,585 2001-09-19
PCT/US2002/029601 WO2003061558A2 (en) 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Publications (2)

Publication Number Publication Date
CA2460749A1 CA2460749A1 (en) 2003-07-31
CA2460749C true CA2460749C (en) 2012-10-23

Family

ID=25497036

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2460749A Expired - Lifetime CA2460749C (en) 2001-09-19 2002-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Country Status (11)

Country Link
US (2) US20030113350A1 (enExample)
EP (1) EP1427442A4 (enExample)
JP (2) JP2005515237A (enExample)
KR (3) KR101090529B1 (enExample)
CN (1) CN1306958C (enExample)
CA (1) CA2460749C (enExample)
EA (1) EA006602B1 (enExample)
MX (1) MXPA04002624A (enExample)
NZ (1) NZ548453A (enExample)
WO (1) WO2003061558A2 (enExample)
ZA (1) ZA200402185B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134677A (zh) * 2009-10-30 2019-01-04 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
NZ539153A (en) 2002-11-12 2006-11-30 Brigham & Womens Hospital Polysaccharide vaccine for staphylococcal infections
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
KR101505496B1 (ko) * 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
ES2372537T3 (es) * 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
AU2008292897B2 (en) * 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
DK2315747T3 (en) 2008-07-21 2018-02-26 Brigham & Womens Hospital Inc Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PL2445522T3 (pl) 2009-06-22 2018-01-31 Wyeth Llc Kompozycje immunogenne antygenów Staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
CA2787184C (en) * 2010-01-19 2016-03-22 Universitatsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
WO2023133143A1 (en) * 2022-01-05 2023-07-13 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134677A (zh) * 2009-10-30 2019-01-04 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化

Also Published As

Publication number Publication date
JP2005515237A (ja) 2005-05-26
MXPA04002624A (es) 2005-02-17
JP2010265293A (ja) 2010-11-25
EA200400448A1 (ru) 2004-12-30
EP1427442A2 (en) 2004-06-16
WO2003061558A9 (en) 2004-06-10
WO2003061558A3 (en) 2003-09-12
EP1427442A4 (en) 2006-06-21
KR101214766B1 (ko) 2012-12-24
US20060188518A1 (en) 2006-08-24
KR20080089527A (ko) 2008-10-06
US7449189B2 (en) 2008-11-11
NZ548453A (en) 2007-07-27
KR101090529B1 (ko) 2011-12-08
CN1306958C (zh) 2007-03-28
ZA200402185B (en) 2005-06-29
CA2460749A1 (en) 2003-07-31
WO2003061558A2 (en) 2003-07-31
KR20100044265A (ko) 2010-04-29
EA006602B1 (ru) 2006-02-24
KR20040070331A (ko) 2004-08-07
US20030113350A1 (en) 2003-06-19
CN1638794A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
CA2460749C (en) Glycoconjugate vaccines for use in immune-compromised populations
Devi et al. Antibodies to poly [(2----8)-alpha-N-acetylneuraminic acid] and poly [(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
KR101298053B1 (ko) 다가 폐렴구균 다당류-단백질 접합체 조성물
US8642042B2 (en) Protein matrix vaccines and methods of making and administering such vaccines
ES2546186T3 (es) Procedimiento de fabricación de vacunas
JP2631035B2 (ja) 多糖類−タンパク質複合体
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
EP4512419A1 (en) Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof
Robbins et al. Haemophilus influenzae type b
Cryz Jr et al. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines
AU2002365253B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
AU2002365253A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
CN101443454A (zh) 多价脑膜炎球菌衍生化的多糖-蛋白质缀合物和疫苗
RU2780425C2 (ru) Композиции neisseria meningitidis и способы
AU662141C (en) Polysaccharide-protein conjugates
Lee Capsule and vaccine development
Bhattacharjee et al. Vaccines Against Bacterial Endotoxins

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220920